Lopinavir

This classification denotes a protease inhibitor with the molecular formula C37H48N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2494G1JF75, chemically known as 1(2h)-pyrimidineacetamide, n-((1s,3s,4s)-4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahyrdo-alpha-1-methylethyl)-2-oxo-, (alphas)- but generally known as lopinavir, which bears US NIH Compound Identifier 92727. European Medicines Agency schedules Lopinavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02970MIG. The term LOPINAVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). World Health Organization schedules lopinavir in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lopinavir under HS 29335995 and SITC 51576. As of Q4 2014, LOPINAVIR remains the US FDA Preferred Term for this commodity. Lopinavir bears US NLM identifiers UMLS ID C0674432 and NCI Concept Code C2095. SMILES: OC(CC(NC(=O)C(N1CCCNC1=O)C(C)C)Cc1ccccc1)C(NC(=O)COc1c(cccc1C)C)Cc1ccccc1.